SFK Inhibitors as New Strategy for RMS Treatment

The outcome of RMS patients is improved in the last decades (5year survival rates of ~70%), however, patients with tumor relapse after treatment or with metastasis at diagnosis are rarely cured [3,4]. Moreover, frequent toxicity and long-term side effects associated with the therapy, dramatically affect the quality of life [1]. Consequently, new specific therapeutic strategies, able to reduce toxicity and side effects, are required for the treatment of RMS. The induction of differentiation and/or cell death through the inhibition of specific enzyme involved in carcinogenesis and tumor progression can be a promising strategy for RMS patients. For instance, several studies focus on the role of epigenetic changes in RMS with the purpose to investigate if the modulation of the activity of some epigenetic enzyme can help to induce apoptosis or differentiation in RMS cells [5-8].